{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:54:36Z","timestamp":1791546876141,"version":"4.3.4"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.103005","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:53:02Z","timestamp":1787932382000},"page":"103005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Modern therapeutic approaches in cholangiocarcinoma: A narrative review of key biomarkers and clinical trials"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-7937","authenticated-orcid":false,"given":"Augusto","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5051-4670","authenticated-orcid":false,"given":"Joao","family":"Manzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-5635","authenticated-orcid":false,"given":"Haaris","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2102-5795","authenticated-orcid":false,"given":"Alan","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-4105","authenticated-orcid":false,"given":"Ana","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Baiyee","family":"Toegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Schulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo M","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Vianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillipe","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0001","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0002","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Ilyas","year":"2013","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.tranon.2026.103005_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","article-title":"Clinical diagnosis and staging of cholangiocarcinoma","volume":"8","author":"Blechacz","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.tranon.2026.103005_bib0005","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1053\/j.gastro.2015.08.046","article-title":"An optimized set of fluorescence In situ hybridization probes for detection of pancreatobiliary tract cancer in cytology brush samples","volume":"149","author":"Barr Fritcher","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0006","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann. Surg."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.tranon.2026.103005_bib0008","article-title":"Gallbladder disorders: a comprehensive review","volume":"67","author":"Lam","year":"2021","journal-title":"Dis-A-Mon: DM"},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0009","article-title":"Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study","volume":"12","author":"Kang","year":"2022","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.tranon.2026.103005_bib0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0011","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40291-015-0167-y","article-title":"Role of circulating cell-free DNA in cancers","volume":"19","author":"Aarthy","year":"2015","journal-title":"Mol. Diagn. Ther."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0012","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2026.103005_bib0013","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.3390\/cancers15123165","article-title":"Cell-free DNA as a surveillance tool for hepatocellular carcinoma patients after liver transplant","volume":"15","author":"Manzi","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.tranon.2026.103005_bib0014","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.tranon.2026.103005_bib0015","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines\u00ae insights: biliary tract cancers, version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw: JNCCN"},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0016","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jgh.70208","article-title":"Systemic therapy for advanced biliary tract cancers in 2026: current standard of care and emerging therapeutic strategies","volume":"41","author":"Yoon","year":"2026","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0017","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"issue":"10391","key":"10.1016\/j.tranon.2026.103005_bib0018","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0019","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0020","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","article-title":"Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations","volume":"34","author":"Pahuja","year":"2018","journal-title":"Cancer Cell."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0021","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2014-0234","article-title":"Oncogenic alterations in ERBB2\/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin","volume":"20","author":"Chmielecki","year":"2015","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.tranon.2026.103005_bib0024","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.3390\/cancers15113023","article-title":"Targeted therapies in colorectal cancer: recent advances in biomarkers, landmark trials, and future perspectives","volume":"15","author":"Manzi","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.humpath.2009.10.002","article-title":"Epidermal growth factor receptor and HER-2\/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder","volume":"41","author":"Shafizadeh","year":"2010","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.tranon.2026.103005_bib0026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2016.08.013","article-title":"Molecular characteristics of biliary tract cancer","volume":"107","author":"Sohal","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"36","key":"10.1016\/j.tranon.2026.103005_bib0027","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3748\/wjg.15.4511","article-title":"EGFR and HER2 expression in advanced biliary tract cancer","volume":"15","author":"Harder","year":"2009","journal-title":"World J. Gastroenterol. 2F: WJG"},{"issue":"36","key":"10.1016\/j.tranon.2026.103005_bib0028","doi-asserted-by":"crossref","first-page":"58007","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.103005_bib0029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","article-title":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","volume":"105","author":"Hiraoka","year":"2020","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev."},{"issue":"1\u20132","key":"10.1016\/j.tranon.2026.103005_bib0031","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000511919","article-title":"ERBB2 Pathway in biliary tract carcinoma: clinical implications of a targetable Pathway","volume":"44","author":"Jacobi","year":"2021","journal-title":"Oncol. Res. Treat."},{"issue":"24","key":"10.1016\/j.tranon.2026.103005_bib0032","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0033","first-page":"42","article-title":"Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest. Cancer Res. GCR"},{"issue":"13","key":"10.1016\/j.tranon.2026.103005_bib0034","first-page":"3384","article-title":"Tumor-inhibitory antibodies to HER-2\/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2","volume":"60","author":"Klapper","year":"2000","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0036","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance Lapatinib versus Placebo after first-line chemotherapy in patients with Human epidermal growth factor receptor 1\/2-positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J. Clin. Oncol: Off J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103005_bib0037","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lungcan.2018.10.019","article-title":"Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: an in vitro study","volume":"126","author":"Koga","year":"2018","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.tranon.2026.103005_bib0038","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin","year":"2022","journal-title":"Cancer Cell."},{"issue":"7","key":"10.1016\/j.tranon.2026.103005_bib0039","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"19_Supplement","key":"10.1016\/j.tranon.2026.103005_bib0040","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2014-CT228","article-title":"Abstract CT228: a phase II study of afatinib (A) in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab (T) refractory esophagogastric (EG) cancer","volume":"74","author":"Janjigian","year":"2014","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.tranon.2026.103005_bib0041","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus Paclitaxel versus Paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: tyTAN\u2014A randomized, phase III study","volume":"32","author":"Satoh","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0042","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0043","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in Human epidermal growth factor receptor 2\u2013Positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: tRIO-013\/LOGiC\u2014A randomized phase III trial","volume":"34","author":"Hecht","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2026.103005_bib0045","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0046","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/cancers13020161","article-title":"Feasibility of HER2-targeted therapy in advanced biliary tract cancer: a prospective pilot study of trastuzumab biosimilar in combination with Gemcitabine Plus Cisplatin","volume":"13","author":"Jeong","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.tranon.2026.103005_bib0047","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"issue":"7390","key":"10.1016\/j.tranon.2026.103005_bib0049","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"7413","key":"10.1016\/j.tranon.2026.103005_bib0050","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature11323","article-title":"IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics","volume":"488","author":"Sasaki","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0051","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","article-title":"Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence","volume":"50","author":"Turcan","year":"2018","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.tranon.2026.103005_bib0052","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0053","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw4543","article-title":"Cancer-associated mutation and beyond: the emerging biology of isocitrate dehydrogenases in human disease","volume":"5","author":"Tommasini-Ghelfi","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.tranon.2026.103005_bib0054","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12626","article-title":"Reproducibility Project: cancer Biology, Reproducibility Project Cancer Biology. Registered report: the common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"5","author":"Fiehn","year":"2016","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0055","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0056","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jos.2021.07.024","article-title":"Prognostic impact of IDH mutations in chondrosarcoma","volume":"27","author":"Nakagawa","year":"2022","journal-title":"J. Orthop. Sci: Off. J. Jpn. Orthop. Assoc."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40610-020-00126-z","article-title":"Is the IDH mutation a good target for chondrosarcoma treatment?","volume":"6","author":"Cojocaru","year":"2020","journal-title":"Curr. Mol. Biol. Rep."},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0058","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/PAS.0000000000001064","article-title":"Immunohistochemical detection and molecular characterization of IDH-mutant sinonasal undifferentiated carcinomas","volume":"42","author":"Mito","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0059","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/path.4915","article-title":"Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas","volume":"242","author":"Dogan","year":"2017","journal-title":"J. Pathol."},{"issue":"11","key":"10.1016\/j.tranon.2026.103005_bib0060","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.5858\/arpa.2018-0224-RS","article-title":"High-grade sinonasal carcinoma: classification through molecular profiling","volume":"143","author":"Guilmette","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0061","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/cancers14061463","article-title":"Towards a molecular classification of sinonasal carcinomas: clinical implications and opportunities","volume":"14","author":"Taverna","year":"2022","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.tranon.2026.103005_bib0062","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0063","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0064","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jmoldx.2018.05.012","article-title":"Multiple ways to detect IDH2 mutations in angioimmunoblastic T-cell lymphoma from immunohistochemistry to next-generation sequencing","volume":"20","author":"Dupuy","year":"2018","journal-title":"J. mol. diagn: JMD"},{"issue":"14","key":"10.1016\/j.tranon.2026.103005_bib0065","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J. Clin. Oncol: Off J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.103005_bib0066","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0067","doi-asserted-by":"crossref","first-page":"721","DOI":"10.31557\/APJCP.2020.21.3.721","article-title":"IDH mutations in AML patients; A higher association with intermediate risk cytogenetics","volume":"21","author":"ElNahass","year":"2020","journal-title":"Asian Pac. J. Cancer Prev. 2F: APJCP"},{"key":"10.1016\/j.tranon.2026.103005_bib0068","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-019-0173-z","article-title":"Isocitrate dehydrogenase inhibitors in acute myeloid leukemia","volume":"7","author":"Liu","year":"2019","journal-title":"Biomark. Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0069","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0070","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MOG.0000000000000050","article-title":"Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma","volume":"30","author":"Grassian","year":"2014","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.tranon.2026.103005_bib0071","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12957-017-1144-1","article-title":"IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing","volume":"15","author":"Lee","year":"2017","journal-title":"World J. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2026.103005_bib0072","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PloS One"},{"issue":"7516","key":"10.1016\/j.tranon.2026.103005_bib0073","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0074","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1245\/s10434-015-5046-6","article-title":"Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients","volume":"23","author":"Ruzzenente","year":"2016","journal-title":"Ann. Surg. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.tranon.2026.103005_bib0075","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2017.35.15_suppl.4015","article-title":"Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts","volume":"35","author":"Lowery","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.tranon.2026.103005_bib0076","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e15675","article-title":"Mutational profiling of resected intrahepatic cholangiocarcinoma","volume":"35","author":"Pak","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.103005_bib0077","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0078","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2026.103005_bib0079","first-page":"711","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet","volume":"4","author":"Lowery","year":"2019","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0081","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0083","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res: Off J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0084","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0085","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.tranon.2026.103005_bib0086","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res: Off J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.tranon.2026.103005_bib0087","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","article-title":"Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach","volume":"179","author":"Presta","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0088","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0089","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"17","key":"10.1016\/j.tranon.2026.103005_bib0090","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res: Off J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.tranon.2026.103005_bib0091","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","article-title":"Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results","volume":"20","author":"Ueno","year":"2020","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.tranon.2026.103005_bib0092","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/bjc.2017.119","article-title":"The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma","volume":"116","author":"Shroff","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0093","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0094","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00280-012-1982-z","article-title":"A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors","volume":"71","author":"Plummer","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0095","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol: Off J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0096","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0097","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0098","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231877","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.tranon.2026.103005_bib0099","doi-asserted-by":"crossref","first-page":"viii319","DOI":"10.1093\/annonc\/mdy283.109","volume":"29","author":"Necchi","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11523-022-00906-w","article-title":"Effect of FGFR2 alterations on overall and progression-free survival in patients receiving systemic therapy for intrahepatic cholangiocarcinoma","volume":"17","author":"Abou-Alfa","year":"2022","journal-title":"Target. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0101","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/acsmedchemlett.3c00006","article-title":"Discovery of Futibatinib: the first covalent FGFR kinase inhibitor in clinical use","volume":"14","author":"Ito","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0102","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.tranon.2026.103005_bib0103","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0104","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF-MEK pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov."},{"issue":"6892","key":"10.1016\/j.tranon.2026.103005_bib0105","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0106","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1358\/dot.2019.55.4.2958476","article-title":"Encorafenib and binimetinib for the treatment of BRAF V600E\/K-mutated melanoma","volume":"55","author":"Rose","year":"2019","journal-title":"Drugs Today"},{"issue":"10","key":"10.1016\/j.tranon.2026.103005_bib0107","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol: Off J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.tranon.2026.103005_bib0108","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1177\/0300060519873481","article-title":"Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience","volume":"47","author":"Kure","year":"2019","journal-title":"J. Int. Med. Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0109","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1530\/EJE-15-0605","article-title":"ENDOCRINE TUMOURS: genetic predictors of thyroid cancer outcome","volume":"174","author":"Tavares","year":"2016","journal-title":"Eur. J. Endocrinol."},{"issue":"17","key":"10.1016\/j.tranon.2026.103005_bib0110","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/1078-0432.CCR-20-1024","article-title":"Population-based screening for BRAF V600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis","volume":"26","author":"Chu","year":"2020","journal-title":"Clin. Cancer Res: Off J. Am. Assoc. Cancer Res."},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0111","doi-asserted-by":"crossref","first-page":"540","DOI":"10.2353\/jmoldx.2006.060070","article-title":"Detection of BRAF V600E mutation in colorectal cancer","volume":"8","author":"Benlloch","year":"2006","journal-title":"J. mol. diagn. 2F: JMD"},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0112","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mds534","article-title":"Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients","volume":"24","author":"Ilie","year":"2013","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0113","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cncr.29042","article-title":"Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium","volume":"121","author":"Villaruz","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0114","doi-asserted-by":"crossref","first-page":"782","DOI":"10.4143\/crt.2021.843","article-title":"Selection strategies and practical application of BRAF V600E-mutated non\u2013Small cell lung carcinoma","volume":"54","author":"Hwang","year":"2022","journal-title":"Cancer Res. Treat. 2F: Off J. Korean Cancer Assoc."},{"issue":"7","key":"10.1016\/j.tranon.2026.103005_bib0115","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert","year":"2014","journal-title":"Mod. Pathol: Off J. U S Can. Acad. Pathol. Inc."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0116","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/j.gastro.2013.01.001","article-title":"Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes","volume":"144","author":"Sia","year":"2013","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.tranon.2026.103005_bib0117","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.humpath.2012.11.006","article-title":"Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions","volume":"44","author":"Voss","year":"2013","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0118","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0119","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0120","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-21-0950","article-title":"Tissue-agnostic activity of BRAF plus MEK inhibitor in BRAF V600-mutant tumors","volume":"21","author":"Adashek","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"15_suppl","key":"10.1016\/j.tranon.2026.103005_bib0121","article-title":"BRAF mutation in Chinese biliary tract cancer patients","volume":"38","author":"Li","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.tranon.2026.103005_bib0122","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0123","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0124","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"33","key":"10.1016\/j.tranon.2026.103005_bib0125","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol: Off J. Am. Soc. Clin. Oncol."},{"issue":"Suppl_8","key":"10.1016\/j.tranon.2026.103005_bib0127","doi-asserted-by":"crossref","first-page":"viii5","DOI":"10.1093\/annonc\/mdz383","article-title":"Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer","volume":"30","author":"Amatu","year":"2019","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0128","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrn1078","article-title":"Neurotrophins and their receptors: a convergence point for many signalling pathways","volume":"4","author":"Chao","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.tranon.2026.103005_bib0129","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pharmthera.2017.02.006","article-title":"Targeting TRK family proteins in cancer","volume":"173","author":"Khotskaya","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2026.103005_bib0131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00183","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2026.103005_bib0132","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/jclinpath-2018-205124","article-title":"TRKA expression and NTRK1 gene copy number across solid tumours","volume":"71","author":"Mauri","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0133","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open."},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0134","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine","volume":"14","author":"Fountzilas","year":"2022","journal-title":"Genome Med."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0136","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0137","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0138","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0139","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res: Off J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2026.103005_bib0141","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","article-title":"Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance","volume":"14","author":"Schram","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0142","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3390\/genes11040424","article-title":"RET gene fusions in malignancies of the thyroid and other tissues","volume":"11","author":"Santoro","year":"2020","journal-title":"Genes"},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0143","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0144","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/d41573-020-00015-1","article-title":"Tumour-agnostic therapies","volume":"19","author":"Looney","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"10","key":"10.1016\/j.tranon.2026.103005_bib0145","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0146","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin. Cancer Res: Off J. Am. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0147","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.tranon.2026.103005_bib0148","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0149","first-page":"472","article-title":"RET kinase alterations in targeted cancer therapy","volume":"3","author":"Liu","year":"2020","journal-title":"Cancer Drug. Resist."},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0151","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41698-021-00188-x","article-title":"The L730V\/I RET roof mutations display different activities toward pralsetinib and selpercatinib","volume":"5","author":"Shen","year":"2021","journal-title":"Npj Precis. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.tranon.2026.103005_bib0152","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA1509","article-title":"Pan-cancer microsatellite instability to predict for presence of Lynch syndrome","volume":"36","author":"Latham Schwark","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.103005_bib0153","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15180","article-title":"A molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"Cortes-Ciriano","year":"2017","journal-title":"Nat. Commun."},{"issue":"7407","key":"10.1016\/j.tranon.2026.103005_bib0154","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.tranon.2026.103005_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015661","article-title":"Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis","volume":"5","author":"Timmermann","year":"2010","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.tranon.2026.103005_bib0156","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin. Cancer Res: Off J. Am. Assoc. Cancer Res."},{"issue":"2","key":"10.1016\/j.tranon.2026.103005_bib0157","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.5139","article-title":"Lynch syndrome - cancer pathways, heterogeneity and immune escape","volume":"246","author":"Seth","year":"2018","journal-title":"J. Pathol."},{"issue":"10","key":"10.1016\/j.tranon.2026.103005_bib0158","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1002\/cam4.2381","article-title":"Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer","volume":"8","author":"Zang","year":"2019","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0159","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ijc.25283","article-title":"Immune evasion of microsatellite unstable colorectal cancers","volume":"127","author":"Kloor","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.tranon.2026.103005_bib0160","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0161","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of Pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol: Off J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.tranon.2026.103005_bib0162","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"26","key":"10.1016\/j.tranon.2026.103005_bib0164","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6349","key":"10.1016\/j.tranon.2026.103005_bib0165","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.tranon.2026.103005_bib0166","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp1709968","article-title":"First FDA approval agnostic of cancer site - when a biomarker defines the indication","volume":"377","author":"Lemery","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.tranon.2026.103005_bib0167","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T cell Co-receptors for cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"issue":"25","key":"10.1016\/j.tranon.2026.103005_bib0168","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line Nivolumab in stage IV or recurrent non\u2013Small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10031","key":"10.1016\/j.tranon.2026.103005_bib0169","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0170","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.103005_bib0171","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx440.040","article-title":"Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC): phase 3 KEYNOTE-040 trial","volume":"28","author":"Cohen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.tranon.2026.103005_bib0172","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0173","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","article-title":"Tumor mutational burden quantification from targeted gene panels: major advancements and challenges","volume":"7","author":"Fancello","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0174","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI insight"},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0175","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"6230","key":"10.1016\/j.tranon.2026.103005_bib0176","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tranon.2026.103005_bib0177","doi-asserted-by":"crossref","first-page":"v761","DOI":"10.1093\/annonc\/mdz268.004","article-title":"Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset","volume":"30","author":"Backenroth","year":"2019","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.tranon.2026.103005_bib0178","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/gcc.22733","article-title":"Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions","volume":"58","author":"Stenzinger","year":"2019","journal-title":"Genes. Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.tranon.2026.103005_bib0179","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann. Oncol: Off J. Eur. Soc. Med. Oncol."},{"issue":"10","key":"10.1016\/j.tranon.2026.103005_bib0180","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1634\/theoncologist.2016-0046","article-title":"Mismatch repair deficiency and response to immune checkpoint blockade","volume":"21","author":"Lee","year":"2016","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.tranon.2026.103005_bib0181","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ajpath.2024.11.005","article-title":"Cholangiocarcinoma targeted therapies: mechanisms of action and resistance","volume":"195","author":"Ellis","year":"2025","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.tranon.2026.103005_bib0182","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Sch\u00f6nherr","year":"2024","journal-title":"Proc. Natl. Acad. Sci."}],"updated-by":[{"DOI":"10.1016\/j.tranon.2026.103061","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000}},{"DOI":"10.1016\/j.tranon.2026.103061","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000}}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326003414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:37:03Z","timestamp":1790739423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326003414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":176,"alternative-id":["S1936523326003414"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103005","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern therapeutic approaches in cholangiocarcinoma: A narrative review of key biomarkers and clinical trials","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.103005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103005"}}